Tests semaglutide in people receiving maintenance dialysis
Tests weekly semaglutide injections against usual care in adults on dialysis.
Plain-language title generated from the registry record
Registry title: Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 4
Where in Canada
- Unity Health TorontoToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Unity Health Toronto
- Trial code
- NCT07017270
- Record updated
- 26 June 2026
- Original description
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.Read full original descriptionShow less
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
Inclusion: Age ≥ 18; Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days; confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin; Ability to provided informed consent or through their substitute decision maker.
Exclusion: Use of a GLP-1-RA within 30 days prior to screening; Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months; Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening); Known hypersensitivity to GLP-1-RA; Type 1 DM; Confirmed pregnancy, women of childbearing potential; Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA.